Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99

Haydar Çelik, Marika Sciandra, Bess Flashner, Elif Gelmez, Neslihan Kayraklıoğlu, David V Allegakoen, Jeff R Petro, Erin J Conn, Sarah Hour, Jenny Han, Lalehan Oktay, Purushottam B Tiwari, Mutlu Hayran, Brent T Harris, Maria Cristina Manara, Jeffrey A Toretsky, Katia Scotlandi, Aykut Üren

Research output: Contribution to journalArticle

Abstract

Ewing sarcoma (ES) is an aggressive bone and soft tissue malignancy that predominantly affects children and adolescents. CD99 is a cell surface protein that is highly expressed on ES cells and is required to maintain their malignancy. We screened small molecule libraries for binding to extracellular domain of recombinant CD99 and subsequent inhibition of ES cell growth. We identified two structurally similar FDA-approved compounds, clofarabine and cladribine that selectively inhibited the growth of ES cells in a panel of 14 ES vs. 28 non-ES cell lines. Both drugs inhibited CD99 dimerization and its interaction with downstream signaling components. A membrane-impermeable analog of clofarabine showed similar cytotoxicity in culture, suggesting that it can function through inhibiting CD99 independent of DNA metabolism. Both drugs drastically inhibited anchorage-independent growth of ES cells, but clofarabine was more effective in inhibiting growth of three different ES xenografts. Our findings provide a novel molecular mechanism for clofarabine that involves direct binding to a cell surface receptor CD99 and inhibiting its biological activities.

Original languageEnglish
Pages (from-to)2181-2196
Number of pages16
JournalOncogene
Volume37
Issue number16
DOIs
Publication statusPublished - Apr 2018

Fingerprint

Ewing's Sarcoma
Growth
Cladribine
Small Molecule Libraries
Cell Surface Receptors
Dimerization
clofarabine
Heterografts
Sarcoma
Pharmaceutical Preparations
Neoplasms
Membrane Proteins
Bone and Bones
Cell Line
Membranes
DNA

Cite this

Çelik, H., Sciandra, M., Flashner, B., Gelmez, E., Kayraklıoğlu, N., Allegakoen, D. V., ... Üren, A. (2018). Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. Oncogene, 37(16), 2181-2196. https://doi.org/10.1038/s41388-017-0080-4

Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. / Çelik, Haydar; Sciandra, Marika; Flashner, Bess; Gelmez, Elif; Kayraklıoğlu, Neslihan; Allegakoen, David V; Petro, Jeff R; Conn, Erin J; Hour, Sarah; Han, Jenny; Oktay, Lalehan; Tiwari, Purushottam B; Hayran, Mutlu; Harris, Brent T; Manara, Maria Cristina; Toretsky, Jeffrey A; Scotlandi, Katia; Üren, Aykut.

In: Oncogene, Vol. 37, No. 16, 04.2018, p. 2181-2196.

Research output: Contribution to journalArticle

Çelik, H, Sciandra, M, Flashner, B, Gelmez, E, Kayraklıoğlu, N, Allegakoen, DV, Petro, JR, Conn, EJ, Hour, S, Han, J, Oktay, L, Tiwari, PB, Hayran, M, Harris, BT, Manara, MC, Toretsky, JA, Scotlandi, K & Üren, A 2018, 'Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99', Oncogene, vol. 37, no. 16, pp. 2181-2196. https://doi.org/10.1038/s41388-017-0080-4
Çelik H, Sciandra M, Flashner B, Gelmez E, Kayraklıoğlu N, Allegakoen DV et al. Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. Oncogene. 2018 Apr;37(16):2181-2196. https://doi.org/10.1038/s41388-017-0080-4
Çelik, Haydar ; Sciandra, Marika ; Flashner, Bess ; Gelmez, Elif ; Kayraklıoğlu, Neslihan ; Allegakoen, David V ; Petro, Jeff R ; Conn, Erin J ; Hour, Sarah ; Han, Jenny ; Oktay, Lalehan ; Tiwari, Purushottam B ; Hayran, Mutlu ; Harris, Brent T ; Manara, Maria Cristina ; Toretsky, Jeffrey A ; Scotlandi, Katia ; Üren, Aykut. / Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. In: Oncogene. 2018 ; Vol. 37, No. 16. pp. 2181-2196.
@article{8f06a150876e4399a64e4dc92cb14717,
title = "Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99",
abstract = "Ewing sarcoma (ES) is an aggressive bone and soft tissue malignancy that predominantly affects children and adolescents. CD99 is a cell surface protein that is highly expressed on ES cells and is required to maintain their malignancy. We screened small molecule libraries for binding to extracellular domain of recombinant CD99 and subsequent inhibition of ES cell growth. We identified two structurally similar FDA-approved compounds, clofarabine and cladribine that selectively inhibited the growth of ES cells in a panel of 14 ES vs. 28 non-ES cell lines. Both drugs inhibited CD99 dimerization and its interaction with downstream signaling components. A membrane-impermeable analog of clofarabine showed similar cytotoxicity in culture, suggesting that it can function through inhibiting CD99 independent of DNA metabolism. Both drugs drastically inhibited anchorage-independent growth of ES cells, but clofarabine was more effective in inhibiting growth of three different ES xenografts. Our findings provide a novel molecular mechanism for clofarabine that involves direct binding to a cell surface receptor CD99 and inhibiting its biological activities.",
author = "Haydar {\cC}elik and Marika Sciandra and Bess Flashner and Elif Gelmez and Neslihan Kayraklıoğlu and Allegakoen, {David V} and Petro, {Jeff R} and Conn, {Erin J} and Sarah Hour and Jenny Han and Lalehan Oktay and Tiwari, {Purushottam B} and Mutlu Hayran and Harris, {Brent T} and Manara, {Maria Cristina} and Toretsky, {Jeffrey A} and Katia Scotlandi and Aykut {\"U}ren",
year = "2018",
month = "4",
doi = "10.1038/s41388-017-0080-4",
language = "English",
volume = "37",
pages = "2181--2196",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "16",

}

TY - JOUR

T1 - Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99

AU - Çelik, Haydar

AU - Sciandra, Marika

AU - Flashner, Bess

AU - Gelmez, Elif

AU - Kayraklıoğlu, Neslihan

AU - Allegakoen, David V

AU - Petro, Jeff R

AU - Conn, Erin J

AU - Hour, Sarah

AU - Han, Jenny

AU - Oktay, Lalehan

AU - Tiwari, Purushottam B

AU - Hayran, Mutlu

AU - Harris, Brent T

AU - Manara, Maria Cristina

AU - Toretsky, Jeffrey A

AU - Scotlandi, Katia

AU - Üren, Aykut

PY - 2018/4

Y1 - 2018/4

N2 - Ewing sarcoma (ES) is an aggressive bone and soft tissue malignancy that predominantly affects children and adolescents. CD99 is a cell surface protein that is highly expressed on ES cells and is required to maintain their malignancy. We screened small molecule libraries for binding to extracellular domain of recombinant CD99 and subsequent inhibition of ES cell growth. We identified two structurally similar FDA-approved compounds, clofarabine and cladribine that selectively inhibited the growth of ES cells in a panel of 14 ES vs. 28 non-ES cell lines. Both drugs inhibited CD99 dimerization and its interaction with downstream signaling components. A membrane-impermeable analog of clofarabine showed similar cytotoxicity in culture, suggesting that it can function through inhibiting CD99 independent of DNA metabolism. Both drugs drastically inhibited anchorage-independent growth of ES cells, but clofarabine was more effective in inhibiting growth of three different ES xenografts. Our findings provide a novel molecular mechanism for clofarabine that involves direct binding to a cell surface receptor CD99 and inhibiting its biological activities.

AB - Ewing sarcoma (ES) is an aggressive bone and soft tissue malignancy that predominantly affects children and adolescents. CD99 is a cell surface protein that is highly expressed on ES cells and is required to maintain their malignancy. We screened small molecule libraries for binding to extracellular domain of recombinant CD99 and subsequent inhibition of ES cell growth. We identified two structurally similar FDA-approved compounds, clofarabine and cladribine that selectively inhibited the growth of ES cells in a panel of 14 ES vs. 28 non-ES cell lines. Both drugs inhibited CD99 dimerization and its interaction with downstream signaling components. A membrane-impermeable analog of clofarabine showed similar cytotoxicity in culture, suggesting that it can function through inhibiting CD99 independent of DNA metabolism. Both drugs drastically inhibited anchorage-independent growth of ES cells, but clofarabine was more effective in inhibiting growth of three different ES xenografts. Our findings provide a novel molecular mechanism for clofarabine that involves direct binding to a cell surface receptor CD99 and inhibiting its biological activities.

U2 - 10.1038/s41388-017-0080-4

DO - 10.1038/s41388-017-0080-4

M3 - Article

C2 - 29382926

VL - 37

SP - 2181

EP - 2196

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 16

ER -